Very common (>10% incidence) adverse effects include insomnia, dizziness, dry mouth, constipation, nausea, and excessive sweating.<ref name = EMC>{{cite web|title=Edronax 4mg Tablets|work=|publisher=UK Electronic Medicines Compendium|date=October 2015|accessdate=20 August 2017|url=http://www.medicines.org.uk/emc/medicine/8386/SPC/Edronax+4mg+Tablets/}}</ref>

 


 
Common (1â€“10%) adverse effects include loss of appetite, agitation, anxiety, headache, restlessness, tingling sensations, distorted sense of taste, difficulty with seeing near or far (problems with [[Accommodation (eye)|accommodation]]), fast heart beat, heart [[palpitations]], relaxing of blood vessels leading to low blood pressure,  high blood pressure, vomiting, rash, sensation of incomplete bladder emptying, urinary tract infection, painful or difficult urination, [[urinary retention]], erectile dysfunction, ejaculatory pain or delay, and chills.<ref name = EMC/>

 


 
A 2009 meta-analysis found that reboxetine was significantly less well-tolerated than the other 11 second-generation antidepressants compared in the analysis.<ref name = Lancet2009/>

 

